newsfilter
← Latest News
GlobeNewswire·

Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates

Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022 Data from its Phase 3 ROMAN trial of avasopasem for SOM will be presented in an oral presentation